A high-throughput yeast assay identifies synergistic drug combinations

Assay and Drug Development Technologies

Volumn 11, Issue 5, 2013, Pages 299-307

  Torres, Nikko P ^a,b   Lee, Anna Y ^a,b   Giaever, Guri ^a,b   Nislow, Corey ^a,b   Brown, Grant W ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROQUINOLINE 1 OXIDE; CAMPTOTHECIN; CHLORMETHINE; CISPLATIN; DOXORUBICIN; IRINOTECAN; MESYLIC ACID METHYL ESTER; METHYLNITRONITROSOGUANIDINE; MITOMYCIN; N (2 FLUORENYL)ACETAMIDE; STREPTOMYCIN; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CONCENTRATION RESPONSE; DRUG ANTAGONISM; DRUG DETERMINATION; DRUG INHIBITION; DRUG POTENTIATION; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; SACCHAROMYCES CEREVISIAE; ANALOGS AND DERIVATIVES; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; NEOPLASMS; PATHOLOGY; PROCEDURES; TUMOR CELL LINE; TWO HYBRID SYSTEM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; HUMANS; MITOMYCIN; NEOPLASMS; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 84879370606     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2012.503     Document Type: Article

References (65)

1. Butcher EC: Can cell systems biology rescue drug discovery? Ernst Schering Res Found Workshop 2005;4:153-172.
2. Lehár J, Krueger AS, Avery W, et al.: Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 2009;27:659-666.
3. Lehár J, Zimmerman GR, Krueger AS, et al.: Chemical combination effects predict connectivity in biological systems. Mol Syst Biol 2007;3:80.
4. Borisy A, Elliott P: Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA 2003;100:7977-7982.
5. Severyn B, Liehr RA, Wolicki A, et al.: Parsimonious discovery of synergistic drug combinations. ACS Chem Biol 2011;6:1391-1398.
6. Tugendreich S, Bassett DE, McKusick VA, Boguski MS, Hieter P: Genes conserved in yeast and humans. Hum Mol Genet 1994;3:1509-1517.
7. Steinmetz LM, Scharfe C, Deutschbauer AM, et al.: Systematic screen for human disease genes in yeast. Nat Genet 2002;31:400-404.
8. Ciccia A, Elledge SJ: The DNA damage response: making it safe to play with knives. Mol Cell 2010;40:179-204.
9. Botstein D, Fink GR: Yeast: an experimental organism for 21st century biology. Genetics 2011;189:695-704.
10. Rouillon C, White MF: The evolution and mechanisms of nucleotide excision repair proteins. Res Microbiol 2011;162:19-26.
11. Brachmann CB, Davies A, Cost GJ, et al.: Designer deletion strains derived from Saccharomyces cerevisiae S288C: a useful set of strains and plasmids for PCR-mediated gene disruption and other applications. Yeast 1998;14: 115-132.
12. Sherman F: Getting started with yeast. Methods Enzymol 1991;194:3-21.
13. Proctor M, Urbanus ML, Fung EL, et al.: The automated cell: compound and environment screening system (ACCESS) for chemogenomic screening. Methods Mol Biol 2011;759:239-269.
14. R Core Team: R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, 2012; at www.r-project.org
15. Bliss C: The toxicity of poisons applied jointly. Ann Appl Biol 1939;26:585-615.
16. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
17. Vichai V, Kirtikara K: Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006;1:1112-1126.
18. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK: Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2006;2:458-466.
19. Jansen G, Lee AY, Epp E, et al.: Chemogenomic profiling predicts antifungal synergies. Mol Syst Biol 2009;5:338.
20. Darzynkiewicz Z, Traganos F, Wlodkowic D: Impaired DNA damage response-an Achilles' heel sensitizing cancer to chemotherapy and radiotherapy. Eur J Pharmacol 2009;625:143-150.
21. Seviour EG, Lin S-Y: The DNA damage response: balancing the scale between cancer and ageing. Aging 2010;2:900-907.
22. Hoeijmakers JHJ: DNA damage, aging, and cancer. N Engl J Med 2009; 361:1475-1485.
23. Negrini S, Gorgoulis VG, Halazonetis TD: Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010;11:220-228.
24. Bixby D, Talpaz M: Efficacy of various doses and schedules of second-generation tyrosine kinase inhibitors. Clin Lymphoma Myeloma 2008;8 Suppl 3:S95-S106.
25. Glendenning J, Tutt A: PARP inhibitors-current status and the walk towards early breast cancer. Breast 2011;20 Suppl 3:S12-S19.
26. Leonard R, Hennessy BT, Blum JL, O'Shaughnessy J: Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer. Clin Breast Cancer 2011;11: 349-356.
27. Maitland M, Hudoba C, Snider K, Ratain M: Analysis of the yield of phase II combination therapy trials in medical oncology. Clin Cancer Res 2010;16: 5296-5302.
28. Chou T-C: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-446.
29. Kano Y, Suzuki K, Akutsu M, et al.: Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 1992;50:604-610.
30. Barker CA, Farha MA, Brown ED: Chemical genomic approaches to study model microbes. Chem Biol 2010;17:624-632.
31. Cokol M, Chua HN, Tasan M, et al.: Systematic exploration of synergistic drug pairs. Mol Syst Biol 2011;7:544.
32. Ejim L, Farha MA, Falconer SB, et al.: Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat Chem Biol 2011;7: 348-350.
33. Kaufmann SH, Peereboom D, Buckwalter CA, et al.: Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 1996;88:734.
34. Wu J, Wheeldon I, Guo Y, et al.: A sandwiched microarray platform for benchtop cell-based high throughput screening. Biomaterials 2011;32: 841-848.
35. Lehár J, Zimmermann G: Chemical combination effects predict connectivity in biological systems. Mol Syst 2007;3:80.
36. Lee W, St Onge RP, Proctor M, et al.: Genome-wide requirements for resistance to functionally distinct DNA-damaging agents. PLoS Genet 2005;1:E24.
37. Grossmann KF, Ward AM, Matkovic ME, Folias AE, Moses RE: S. cerevisiae has three pathways for DNA interstrand crosslink repair. Mutat Res 2001;487:73-83.
38. Sarkar S, Davies AA, Ulrich HD, McHugh PJ: DNA interstrand crosslink repair during G1 involves nucleotide excision repair and DNA polymerase zeta. EMBO J 2006;25:1285-1294.
39. Deweese JE, Osheroff N: The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. Nucleic Acids Res 2009;37:738-748.
40. Kule C, Ondrejickova O, Verner K: Doxorubicin, daunorubicin, and mitoxantrone cytotoxicity in yeast. Mol Pharmacol 1994;46:1234-1240.
41. Beranek DT: Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. Mutat Res 1990;231:11-30.
42. Hurley LH: DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer 2002;2:188-200.
43. Otteneder M, Lutz WK: Correlation of DNA adduct levels with tumor incidence: carcinogenic potency of DNA adducts. Mutat Res 1999;424:237-247.
44. Shrivastav N, Li D, Essigmann JM: Chemical biology of mutagenesis and DNA repair: cellular responses to DNA alkylation. Carcinogenesis 2010;31:59-70.
45. Wyatt MD, Pittman DL: Methylating agents and DNA repair responses: methylated bases and sources of strand breaks. Chem Res Toxicol 2006;19:1580-1594.
46. Olive PL, Banáth JP: The comet assay: a method to measure DNA damage in individual cells. Nat Protoc 2006;1:23-29.
47. Wang D, Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307-320.
48. Kingma PS, Osheroff N: The response of eukaryotic topoisomerases to DNA damage. Biochim Biophys Acta 1998;1400:223-232.
49. Pommier Y, Leo E, Zhang H, Marchand C: DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010;17:421-433.
50. Randall ME, Filiaci VL, Muss H, et al.: Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2006;24:36-44.
51. Takano M, Sugiyama T, Yaegashi N, et al.: Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis. Int J Clin Oncol 2007;12:256-260.
52. Tardi PG, Dos Santos N, Harasym TO, et al.: Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol Cancer Ther 2009;8:2266-2275.
53. Lee MJ, Ye AS, Gardino AK, et al.: Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012;149: 780-794.
54. Eder J, Chan V, Wong J, Wong Y: Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo. Cancer Chemother Pharmacol 1998;42: 327-335.
55. Kim R, Hirabayashi N, Nishiyama M, et al.: Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer 1992;50:760-766.
56. Heaney ML, Gardner JR, Karasavvas N, et al.: Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 2008;68:8031-8038.
57. Daroui P, Desai SD, Li T-K, Liu AA, Liu LF: Hydrogen peroxide induces topoisomerase I-mediated DNA damage and cell death. J Biol Chem 2004;279: 14587-14594.
58. Belguise-Valladier P, Fuchs RP: N-2-aminofluorene and N-2 acetylaminofluorene adducts: the local sequence context of an adduct and its chemical structure determine its replication properties. J Mol Biol 1995;249: 903-913.
59. Kato K, Yamamura E, Kawanishi M, et al.: Application of the DNA adductome approach to assess the DNA-damaging capability of in vitro micronucleus test-positive compounds. Mutat Res 2011;721:21-26.
60. Arima Y, Nishigori C, Takeuchi T, et al.: 4-Nitroquinoline 1-oxide forms 8-hydroxydeoxyguanosine in human fibroblasts through reactive oxygen species. Toxicol Sci 2006;91:382-392.
61. Miranda SR, Noguti J, Carvalho JG, Oshima CTF, Ribeiro DA: Oxidative DNA damage is a preliminary step during rat tongue carcinogenesis induced by 4-nitroquinoline 1-oxide. J Mol Histol 2011;42:181-186.
62. Iwamoto T, Kobayashi N, Imoto K, et al.: In situ detection of acetylaminofluorene-DNA adducts in human cells using monoclonal antibodies. DNA Repair 2004; 3:1475-1482.
63. Evans TJ, Yamamoto KN, Hirota K, Takeda S: Mutant cells defective in DNA repair pathways provide a sensitive high-throughput assay for genotoxicity. DNA Repair 2010;9:1292-1298.
64. Tercero JA, Diffley JF: Regulation of DNA replication fork progression through damaged DNA by the Mec1/Rad53 checkpoint. Nature 2001;412:553-557.
65. Sabourin M, Osheroff N: Sensitivity of human type II topoisomerases to DNA damage: stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions. Nucleic Acids Res 2000;28:1947-1954.